Advertisement
About the SEPET(TM) Liver Assist Device
The SEPET(TM) Liver Assist Device is a sterile, disposable cartridgecontaining microporous hollow fibers with proprietary permeabilitycharacteristics. When a patient's blood is passed through these fibers, bloodplasma components of specific molecular weights are expressed through themicropores, thereby cleansing the blood of harmful impurities (i.e., hepaticfailure toxins as well as various mediators of inflammation and inhibitors ofliver regeneration). These substances would otherwise progressivelyaccumulate in the patient's bloodstream during liver failure, causinghypotension, increasing risk of sepsis development and accelerating damage tothe liver, lungs and other organs, including the brain and kidneys, andsuppressing the function and regeneration of the liver. SEPET(TM) is designedfor use with standard blood dialysis systems available in hospital intensivecare units.
Advertisement
About Arbios Systems
Arbios Systems, Inc. is developing proprietary medical devices and cell-based therapies to enhance the survival of millions of patients each year whoexperience, or are at risk for, life-threatening episodes of liver failure.The Arbios product candidate portfolio includes the SEPET(TM) Liver AssistDevice, a novel blood purification therapy that provides enhanced "liverdialysis," and the HepatAssist(TM) Cell-Based Liver Support System, abioartificial liver that combines blood detoxification with liver cell therapyto replace whole liver function in patients with the most severe forms ofliver failure. For more information on ABOS.OB, please visithttp://www.arbios.com .
Scimitar Equity Research, Inc. provides sponsored equity research of thehealthcare industry for the institutional and investment communities. Wecertify that all the views expressed in this review, accurately reflect ourpersonal views about ABOS.OB (NASDAQ: OTC: BB) and its or their securities.No part of our compensation was, is, or will be, directly or indirectly,related to the specific recommendations or views contained in this review andwe will not have any investment banking relationships or personal investmentin any sponsored company. Investors are advised that this analysis and reviewis issued solely for informational purposes and is not to be construed as anoffer to sell or the solicitation of an offer to buy. Scimitar was paid forpreparing this review. This analysis and review does not have regard to thespecific investment objectives, financial situation and the informationcontained herein is based on sources that we believe to be reliable but is notguaranteed by us as being accurate. Any opinions expressed are statements ofour own judgment as of the date of publication and are subject to changewithout notice. Please read all our important disclosures.CONTACT: Scimitar Equity Research, Inc. Henry W. McCusker Director of Research phone: (617) 559-1080 fax: (617) 559-1083 e-mail: [email protected]
SOURCE Scimitar Equity Research, Inc.
